Data / Form D filings / Deka Biosciences, Inc.
Deka Biosciences, Inc.: Form D filings
Deka Biosciences, Inc., a biotechnology company in Germantown, MD, filed 2 Form D notices with the SEC between 2021 and 2023. The latest, on December 8, 2023, reports $29.9 million sold of a $41.4 million offering to 33 investors.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 20378 SENECA MEADOWS PKWY, Germantown, MD, 20876
- Phone
- (301) 569-4323
- Industry
- Biotechnology
- Entity type
- Corporation
- Incorporated in
- Delaware
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1893069
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Dec 8, 2023 | New notice | $41,386,483 | $29,851,474 | $11,535,009 | 33 | Feb 6, 2023 | sec.gov |
| Nov 23, 2021 | New notice | $25,886,661 | $15,886,660 | $10,000,001 | 28 | Oct 29, 2021 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| John Mumm | Executive Officer, Director | |
| Pavel Khrimian | Executive Officer | |
| Detlev Biniszkiewicz | Director | |
| Lu Han | Director | |
| Christopher Yaen | Executive Officer | |
| Rakhshita Dhar | Director | |
| Peter Buzy | Director |
Other biotechnology companies in Maryland that filed recently
- Accufy Diagnostics, Inc. $2 million · Oct 28, 2026
- OS Therapies Inc $7.2 million · Oct 23, 2026
- Kaigene, Inc. $55 million · Oct 14, 2026
- Templar Nova, Inc. $7 million · Oct 7, 2026
- Monocacy Therapeutics Inc. $25,000 · Oct 7, 2026
- Seraxis Holdings, Inc. $10 million · Sep 24, 2026
Every Form D from the week of Dec 4, 2023 · All recent filings in Maryland · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what Deka Biosciences, Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.